




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 209/42, 409/14, 403/12, 401/12, A61K 31/40		A1	(11) International Publication Number: WO 00/46195
			(43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/GB00/00260		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GI, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 31 January 2000 (31.01.00)			
(30) Priority Data: 9902459.8 5 February 1999 (05.02.99) GB			
(71) Applicant (for all designated States except US): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): FAULL, Alan, Welling- ton [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). KETTLE, Jason [GB/GB]; Alderley Park, Mac- clesfield, Cheshire SK10 4TG (GB).		Published <i>With international search report.</i>	
(74) Agent: BRYANT, Tracey; Global Intellectual Property, Patents, AstraZeneca UK Limited, Mereside, Alderley Park, Macclesfield Cheshire SK10 4TG (GB).			

(54) Title: ANTI-INFLAMMATORY INDOLE DERIVATIVES



(57) Abstract

Therapeutic compounds of formula (I) wherein X is CH₂ or SO₂; R¹ is an optionally substituted aryl or heteroaryl ring; R² and R³ are various specified groups, R⁴ is a group NHCOR¹⁵, NHSO₂R¹⁵ or OCONR¹⁶R¹⁷ where R¹⁵ is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl and R¹⁶ and R¹⁷ are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R¹⁶ or R¹⁷ is other than hydrogen, or R¹⁶ and R¹⁷ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and R⁵, R⁶ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R⁴ is a group NHCOR¹⁵, R¹⁵ is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTI-INFLAMMATORY INDOLE DERIVATIVES

The present invention relates to chemical compounds, to their production as well as to pharmaceutical compositions containing them as well as to their use in therapy, in particular
5 of inflammatory disease.

MCP-1 is a member of the chemokine family of pro-inflammatory cytokines which mediate leukocyte chemotaxis and activation. MCP-1 is a C-C chemokine which is one of the most potent and selective T-cell and monocyte chemoattractant and activating agents known. MCP-1 has been implicated in the pathophysiology of a large number of inflammatory
10 diseases including rheumatoid arthritis, glomerular nephritides, lung fibrosis, restenosis (International Patent Application WO 94/09128), alveolitis (Jones et al., 1992, *J. Immunol.*, 149, 2147) and asthma. Other disease areas where MCP-1 is thought to play a part in their pathology are atherosclerosis (e.g. Koch et al., 1992, *J. Clin. Invest.*, 90, 772-779), psoriasis (Deleuran et al., 1996, *J. Dermatological Science*, 13, 228-236), delayed-type
15 hypersensitivity reactions of the skin, inflammatory bowel disease (Grimm et al., 1996, *J. Leukocyte Biol.*, 59, 804-812), multiple sclerosis and brain trauma (Berman et al, 1996, *J. Immunol.*, 156, 3017-3023). An MCP-1 inhibitor may also be useful to treat stroke, reperfusion injury, ischemia, myocardial infarction and transplant rejection.

MCP-1 acts through the MCP-1 receptor (also known as the CCR2 receptor). MCP-2
20 and MCP-3 may also act, at least in part, through the MCP-1 receptor. Therefore in this specification, when reference is made to "inhibition or antagonism of MCP-1" or "MCP-1 mediated effects" this includes inhibition or antagonism of MCP-2 and/or MCP-3 mediated effects when MCP-2 and/or MCP-3 are acting through the MCP-1 receptor.


Copending International Patent Application Nos. PCT/GB98/02340 and
25 PCT/GB98/02341 describe and claim groups of compounds based upon the indole ring structure which are inhibitors of MCP-1 and therefore have applications in therapy.

The use of certain indole derivatives as NMDA antagonists is described in
USP5051442, WO9312780, EP-483881. Other indoles and their use as inhibitors of
leukotriene biosynthesis is described in for example, EP-A- 275-667.

The applicants have found a particular substitution on the indole ring produces advantageous results when used therapeutically as inhibitors of MCP-1.

According to the present invention there is provided a compound of formula (I)

5




(I)

X is CH₂ or SO₂

10 R¹ is an optionally substituted aryl or heteroaryl ring;

R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁸, -SO₂NHR⁹, tetrazol-5-yl, SO₃H, or a group of formula (VI)



(VI)

15 where R⁸ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO₂R¹² where R¹² is alkyl, aryl, heteroaryl, or haloalkyl, or R⁸ is a group-(CHR¹³)_r-COOH where r is an integer of 1-3 and each R¹³ group is independently selected from hydrogen or alkyl; R⁹ is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR¹⁴ where R¹⁴ is alkyl,
20 aryl, heteroaryl or haloalkyl; R¹⁰ and R¹¹ are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl;

R³ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy, optionally substituted cycloalkyl;

- 5 R⁴ is a group NHCOR¹⁵, NHSO₂R¹⁵ or OCONR¹⁶R¹⁷ where R¹⁵ is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl and R¹⁶ and R¹⁷ are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R¹⁶ or R¹⁷ is other than hydrogen, or R¹⁶ and R¹⁷ together with the nitrogen atom to which they
10 are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and

R⁵, R⁶ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbonyl groups or optionally substituted heterocyclic groups.

- Suitably, where R⁴ is a group NHCOR¹⁵, R¹⁵ is substituted alkyl, optionally
15 substituted aryl or optionally substituted heteroaryl.

Compounds of formula (I) are inhibitors of monocyte chemoattractant protein-1. In addition, they appear to inhibit RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), induced chemotaxis. RANTES is another chemokine from the same family as MCP-1, with a similar biological profile, but acting through the CCR1
20 receptor. As a result, these compounds can be used to treat disease mediated by these agents, in particular inflammatory disease.

In this specification the term 'alkyl' when used either alone or as a suffix includes straight chained, branched structures. These groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. Similarly the terms "alkenyl" and "alkynyl" refer
25 to unsaturated straight or branched structures containing for example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as "alkoxy" comprise alkyl groups as is understood in the art.

The term "halo" includes fluoro, chloro, bromo and iodo. References to aryl groups
30 include aromatic carbocyclic groups such as phenyl and naphthyl. The term "heterocyclyl" includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen.

Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinoliny, isoquinoliny, quinoxaliny, benzothiazolyl, benzoxazolyl, benzothiényl or benzofuryl.

5 "Heteroaryl" refers to those groups described above which have an aromatic character. The term "aralkyl" refers to aryl substituted alkyl groups such as benzyl.

Other expressions used in the specification include "hydrocarbyl" which refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.

10 The term "functional group" refers to reactive substituents. They may comprise electron-donating or electron-withdrawing. Examples of such groups include halo, cyano, nitro, $C(O)_nR^{18}$, OR^{18} , $S(O)_mR^{18}$, $NR^{19}R^{20}$, $C(O)NR^{19}R^{20}$, $OC(O)NR^{19}R^{20}$, $-NR^{19}C(O)_nR^{18}$, $-NR^{18}CONR^{19}R^{20}$, $-N=CR^{19}R^{20}$, $S(O)_mNR^{19}R^{20}$ or $-NR^{19}S(O)_mR^{18}$ where R^{18} , R^{19} and R^{20} are independently selected from hydrogen or optionally substituted hydrocarbyl, or R^{19} and R^{20} together form an optionally substituted ring which optionally contains further heteroatoms such as $S(O)_m$, oxygen and nitrogen, n is an integer of 1 or 2, m is 1 or 2.

Suitable optional substituents for hydrocarbyl groups R^{18} , R^{19} and R^{20} include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, carboxy, alkoxy, heteroaryl, heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyalkoxy, aryloxy (where the aryl group may be substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, oximino or $S(O)_nR^x$ where n is as defined above and R^x is alkyl such as C_{1-4} alkyl.


Suitable substituents for these hydrocarbyl or heterocyclic groups include those listed above for R^{18} , R^{19} and R^{20} .

Suitably R^1 is an optionally substituted phenyl, pyridyl, naphthyl, furyl or thienyl ring, and in particular is a substituted phenyl or pyridyl ring.

Suitable optional substituents for R^1 in formula (I) include alkyl, alkenyl, alkynyl, halo, haloalkyl including perhaloalkyl such as trifluoromethyl, mercapto, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, hydroxyalkoxy, alkoxyalkoxy, alkanoyl, alkanoyloxy, cyano, nitro, amino, mono- or di-alkyl amino, oximino, sulphonamido, carbamoyl, mono or dialkylcarbamoyl or $S(O)_mR^{21}$ where m is as defined above and R^{21} is hydrocarbyl.

Particular examples of substituents R^5 , R^6 and R^7 , and where appropriate also R^4 include hydrogen, hydroxy, halo, optionally substituted alkyl such as aralkyl, carboxyalkyl or

the amide derivative thereof; alkoxy; aryloxy; aralkyloxy; or an amino group which is optionally substituted with alkyl, aryl or aralkyl. A specific functional group which is suitable for R^4 , R^5 , R^6 and/or R^7 is a group of sub-formula (IV).



(IV)

Particular examples of groups R^5 , R^6 and R^7 are hydrogen, hydroxy, halo or alkoxy. In particular R^6 and R^7 are hydrogen. R^5 may be hydrogen but in addition is suitably a small substituent such as hydroxy, halo or methoxy.


Particular substituents for R^1 include trifluoromethyl, C_{1-4} alkyl, halo, trifluoromethoxy, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, nitro, carbamoyl, C_{1-4} alkoxycarbonyl, C_{1-4} alkylsulphanyl, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, sulphonamido, carbamoyl C_{1-4} alkyl, N -(C_{1-4} alkyl)carbamoyl C_{1-4} alkyl, N -(C_{1-4} alkyl)₂carbamoyl- C_{1-4} alkyl, hydroxy C_{1-4} alkyl or C_{1-4} alkoxy C_{1-4} alkyl.

Additionally or alternatively, two such substituents together may form a divalent radical of the formula $-O(CH_2)_{1-4}O-$ attached to adjacent carbon atoms on the R^1 ring.

Preferred substituents for R^1 are one or more non-polar substituents such as halo.

In particular, R^1 is substituted by one or more halo groups, in particular chlorine. A particular example of an R^1 group is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

Examples of groups R^2 include carboxy; cyano; tetrazol-5-yl; SO_3H ; $-CONHR^8$ where R^8 is selected from cyano, hydroxy, $-SO_2R^{12}$ where R^{12} is alkyl such as C_{1-4} alkyl, aryl such as phenyl, heteroaryl or trifluoromethyl, or R^8 is a group $-(CHR^{10})_r-COOH$ where r is an integer of 1-3 and each R^{10} group is independently selected from hydrogen or alkyl such as C_{1-4} alkyl; or R^2 is a group $-SO_2NHR^9$ where R^9 is an optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl group, or a group COR^{14} where R^{14} is alkyl such as C_{1-4} alkyl, aryl such as phenyl, heteroaryl or trifluoromethyl, or R^2 is a group of formula (VI)



(VI)

where R^{10} and R^{11} are independently selected from hydrogen or alkyl, particularly C_{1-4} alkyl.

5 Preferably R^2 is carboxy or a pharmaceutically acceptable salt or ester thereof.

Suitable groups R^3 include hydrogen, fluoro, chloro, bromo, iodo, methyl, cyano, trifluoromethyl, hydroxymethyl, alkoxyalkyl such as C_{1-4} alkoxymethyl, methoxy, benzyloxy, carboxyalkoxy such as carboxymethoxy, methylsulphanyl, methylsulphinyl, methylsulphonyl or carboxy C_{3-6} cycloalkyl, $-(CHR^{22})_r-NR^{23}R^{24}$ (where r is 0-2, each R^{22} is independently
10 hydrogen or alkyl, in particular C_{1-4} alkyl, R^{23} and R^{24} are independently selected from H and C_{1-4} alkyl or R^{23} and R^{24} together with the nitrogen to which they are attached form a 5 or 6 membered ring optionally containing one further heteroatom selected from O, N, S, S(O) or SO_2 . Suitably R^{23} and R^{24} together form a heterocyclic ring such as morpholino or piperazinyl.

Other such groups R^3 include optionally substituted aryl groups, such as optionally
15 substituted phenyl or naphthyl group. Suitable substituents for phenyl groups R^3 include one or more groups selected from chlorine, fluorine, methyl, trifluoromethyl, trifluoromethoxy, amino, formyl, phenyl, methoxy, phenoxy or phenyl.

R^3 may comprise a range of substituents as listed above, in particular, hydrogen or a small substituent group such as C_{1-4} alkyl in particular methyl, or trifluoromethyl, and is
20 preferably hydrogen.

Suitable optional substituents for the group R^{15} , R^{16} and R^{17} as they appear in the definition of R^4 , include functional groups as hereinbefore defined, as well as aryl or heterocyclyl groups, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.

25 Particular examples of substituents for groups R^{15} , R^{16} and R^{17} include one or more groups selected from halo such as chloro; hydroxy; cyano; amino; mono- or di-alkylamino; C_{1-4} alkoxy; carboxy; sulphonamido; $CONH_2$; alkylamido where the alkyl moiety is optionally substituted for example with a functional groups such as carboxy; morpholino;

pyridyl; pyrimidinyl; phenyl optionally substituted by halo such as chloro, hydroxy, alkoxy such as methoxy, carbamoyl, acyl such as acetyl, or hydroxyalkyl where the alkyl group suitably includes at least two carbon atoms, such as hydroxyethyl. Other examples of substituents for phenyl groups R^{15} is alkanoylamino group such as methoylamino.

5 Where R^{15} , R^{16} and/or R^{17} is a heterocyclyl group, or where R^{16} and R^{17} together form an optionally substituted heterocyclic ring, these may be substituted by functional groups such as halo or hydroxy, or by alkyl groups such as methyl or ethyl, or alkenyl or alkynyl groups any of which may be substituted, for example with hydroxy, as well as with further heteroaryl groups such as pyridyl. Particular examples of heterocyclic groups R^{15} , R^{16}
10 and/or R^{17} are optionally substituted thiophenyl, optionally substituted imidazolyl, optionally substituted pyridyl.

Thus thiophenyl groups R^{15} , R^{16} and/or R^{17} may comprise pyridyl-thiophenyl, whilst an example of a substituted imidazolyl group for R^{15} , R^{16} and/or R^{17} is methylimidazolyl and halopyridyl in particular chloropyridyl is an example of a substituted pyridyl moiety for these
15 groups.

Particular examples of R^{15} include alkyl in particular methyl optionally substituted by a functional groups or, in particular, a heterocyclyl group where the heterocyclyl group may be optionally substituted by a functional group such as halo or hydroxy or by an alkyl group such as methyl. Preferably, R^{15} is a substituted alkyl group. Where the substituent is a
20 functional group, it is preferably a group of formula $NR^{19}R^{20}$ where R^{19} and R^{20} are as defined above. Thus examples of substituted alkyl groups R^{15} include morpholinomethyl or alkyl such as methyl substituted with a substituted alkyl amino group wherein the substituents include carboxy, alkanoyl, phenyl or alkyl sulphonyl.

Other examples of R^{15} are heterocyclyl groups which are optionally substituted for
25 example by alkyl such as methyl, functional groups such as chloro or heterocyclyl groups such as pyridyl.

Particular examples of R^{16} and R^{17} are alkyl such as methyl.

X is CH_2 or SO_2 and is preferably CH_2 .

Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid
30 addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for

example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, dibenzylamine, *N,N*-dibenzylethylamine or amino acids for example lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred

5 pharmaceutically acceptable salt is a sodium salt.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.

Suitable pharmaceutically acceptable esters for carboxy include alkyl esters, such as


10 C₁₋₆ alkyl esters for example, ethyl esters, C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxy-carbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 15 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

Suitable pharmaceutically acceptable esters of compounds of formula (I) are *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds 20 which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and 25 *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

Esters which are not *in vivo* hydrolysable are useful as intermediates in the production of the compounds of formula (I) and therefore these form a further aspect of the invention.








Thus examples of compounds of formula (I) include the following:

Table 1



5


Compd No.	R ³	R ⁴	R ⁵	R ⁶	R ^a	R ^b
1	H		H	H	H	H
2	H		H	H	Cl	Cl
3	H		H	H	Cl	Cl
4	H		H	H	Cl	Cl
5	H		H	H	Cl	Cl

6	H		H	H	Cl	Cl
7	H		H	H	Cl	Cl
8	H	$\text{NHC(O)CH}_2\text{NHCH}_2\text{COOH}$	H	H	Cl	Cl
9	H		H	H	Cl	Cl
10	H	$\text{OC(O)N(CH}_3)_2$	H	H	Cl	Cl
11	H		H	H	Cl	Cl
12	H		H	H	Cl	Cl
13	H		H	H	Cl	Cl
14	H	$\text{NHC(O)CH}_2\text{N(CH}_3)_2\text{CH}_2\text{COOH}$	H	H	Cl	Cl
15	H		H	H	Cl	Cl

where * indicates the point of attachment of the group to the indole ring.

Compounds of formula (I) are suitably prepared by methods such as those described in International Patent Application Nos. PCT/GB98/02340 and PCT/GB98/02341.

In particular compounds of formula (I) where R^4 is NHCOR^{15} or $\text{NHSO}_2\text{R}^{15}$ can be prepared by reacting a compound of formula (VII)



(VII)

where X, R^1 , R^3 , R^5 , R^6 and R^7 are as defined in relation to formula (I). R^2 is a group R^2 as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)

where Z is a leaving group and R^{22} is a group $\text{COR}^{15'}$ or $\text{SO}_2\text{R}^{15'}$ where $R^{15'}$ is group R^{15} as defined in relation to formula (I) or a precursor thereof;


and thereafter if desired or necessary:

- (i) converting a precursor group $R^{15'}$ to a group R^{15} and/or converting a group R^{15} to a different such group;
- (ii) deprotecting a group $R^{2'}$ to a group R^2 .

Suitable leaving groups Z include halo such as chloro.

The reaction is suitably effected in an organic solvent such as dichloromethane or tetrahydrofuran in the presence of a base such as triethylamine or pyridine. Moderate temperatures, for example from 0° to 50°C and conveniently ambient temperature, are employed in the reaction.

Compounds of formula (I) where R^4 is a group $\text{OCONR}^{16}\text{R}^{17}$ may be prepared by a broadly similar method by reacting a compound of formula (VIIA)



(VIIA)

where X, R^{2'}, R¹, R³, R⁵, R⁶ and R⁷ are as defined in relation to formula (I), R² is a group R² as defined in relation to formula (I) or a protected form thereof, with a compound of formula


5 (VIIIA)



(VIIIA)

where Z, R¹⁶ and R¹⁷ are as defined above.


10 Compounds of formula (VIIA) can be prepared by reacting a compound of formula (IX)



(IX)

where R³, R⁵, R⁶ and R⁷ are as defined in relation to formula (I) and R^{2'} is as defined in

15 relation to formula (VII) and R⁴⁰ is a protecting group; with compound of formula (X)



(X)

20 where R¹ and X are as defined in relation to formula (I) and Z¹ is a leaving group, and thereafter, removing the protecting group R⁴⁰.


Suitable leaving groups for Z include halide such as chloride, bromide or iodide, as well as mesylate or tosylate. The reaction is suitably effected in an organic solvent such as dimethylformamide (DMF) tetrahydrofuran (THF) or DCM in the presence of a base such as sodium hydride, sodium hydroxide, potassium carbonate. Optionally the reaction is effected
5 in the presence of a suitable phase transfer catalyst. The choice of base and solvent is interdependent to a certain extent in that certain solvents are compatible with some bases only as is understood in the art. For example, sodium hydride may preferably be used with dimethylformamide or tetrahydrofuran and sodium hydroxide is preferably used with dichloromethane and a phase transfer catalyst.

10 The reaction can be carried out at moderate temperatures, for example from 0 to 50°C and conveniently at about ambient temperature.

Preferably, R² is an ester group in the compound of formula IX and this may be subsequently converted to an acid or to another ester or salt, by conventional methods later in the process. For example, when X is a group SO₂ and R² is a methyl ester of carboxy, it may
15 be converted to the corresponding carboxylic acid by reaction with lithium iodide in dry pyridine or DMF.

Suitable protecting groups R⁴⁰ include acetyl or benzyl. The reaction conditions employed will be variable depending upon the nature of the protecting group R⁴⁰ and would be apparent to a skilled person. Acetyl groups may be removed by reaction with a strong
20 base such as sodium methoxide, whereas benzyl groups may be removed by hydrogenation for example in the presence of a catalyst such as a palladium catalyst.

Compounds of formula (IX) may be prepared by cyclisation of a compound of formula (XII)



(XII)


where R^5 , R^6 , R^7 and R^{40} are as defined above and R^{42} and R^{43} represent a combination of moieties which can cyclise to form an appropriately substituted pyrrole ring. For example, one of R^{42} and R^{43} can be a group of formula $-\text{CH}=\text{C}(\text{R}^{44})\text{N}_3$, where R^{44} is a group R^2 as defined above, or a protected form thereof, and the other may be hydrogen. Cyclisation to

5 form a compound of formula (XII) may then be effected by heating for example under reflux in an organic solvent, in particular a high boiling aprotic solvent such as xylene or toluene.

Alternatively, one of R^{42} and R^{43} may be nitro and the other may be a group of formula $-\text{CH}_2\text{C}(\text{O})\text{R}^{2'}$ where $R^{2'}$ is as defined above in relation to formula (VII). These compounds will cyclise in the presence of a catalyst such as palladium on carbon in the


10 presence of hydrogen. The reaction may be effected at moderate temperatures for example of from 0 to 80°C, conveniently at about ambient temperature.

Thus examples of compounds of formula (XII) include compounds of formula (XIII) and (XIV)



15


(XIII)



20

(XIV)

Compounds of formula (XIII) where R^3 is hydrogen may be prepared for example by reacting a compound of formula (XV)



(XV)

with a compound of formula (XVI)



(XVI)

- 10 where R^5 , R^6 , R^7 , and $R^{2'}$ are as defined hereinbefore. The reaction may be effected in an organic solvent such as ethanol at low temperatures of from -20 to 0°C , suitably at about 0°C . The reaction is suitably effected in the presence of a base such as an alkoxide, in particular an ethoxide, for example potassium ethoxide.


Compounds of formula (XVI) are suitably prepared by reacting a compound of
15 formula (XVII)



(XVII)

where $R^{2'}$ is defined above and R^{47} is a leaving group such as halide and in particular bromide, with an azide salt, such as an alkali metal azide salt in particular sodium azide.


- 20 Compounds of formula (XIV) may be prepared by reacting a compound of formula (XVIII)



(XVIII)

where R^5 , R^6 , R^7 , R^3 , R^{40} and $R^{2'}$ are as defined above, with a compound of formula (XIX)


5



(XIX)

where $R^{2'}$ is as defined above and R^{48} leaving group such as hydroxy. Examples of compounds of formula (XVI) are oxalates such as diethyloxalate. The reaction is suitably effected in the presence of a base such as sodium hydride in an organic solvent such as THF. Moderate temperatures of from 0° to 40°C and conveniently ambient temperature is employed.


Compounds of formula (VII) are suitably prepared using a reaction analogous to that between compounds (IX) and (X), where in place of the compound of formula (IX), a compound of formula (IXA) is employed



(IXA)

where $R^{2'}$, R^3 , R^5 , R^6 and R^7 are as defined above. Such compounds may be obtained by reduction of the corresponding nitro compound of formula (XX)

20



(XX)

where R^{2'}, R³, R⁵, R⁶ and R⁷ are as defined above.

Compounds of formula (X), (XVI), (XV), (XVII), (XVIII), (XIX) and (XX) are either
 5 known compounds or they may be prepared from known compounds by conventional literature methods.

According to a further aspect of the invention there is provided a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, for use in a method of treatment of the human or animal body by therapy. In
 10 particular, the compounds are used in methods of treatment of inflammatory disease.

According to a further aspect of the present invention there is provided a method for antagonising an MCP-1 mediated effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable
 15 ester thereof.

The invention also provides a pharmaceutical composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof, in combination with a pharmaceutically acceptable diluent or carrier.

The compositions of the invention may be in a form suitable for oral use (for example
 20 as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile
 25 aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended

for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents
5 may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting
10 agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable
15 emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative
20 agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable
25 aqueous or oily suspension; which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

30 Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal

temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a
5 conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 μ or much less, the powder itself comprising either active ingredient alone or diluted with one or more
10 physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional
15 pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in
20 Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration
25 to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in
30 Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in
5 treating diseases or medical conditions which are due alone or in part to the effects of farnesylation of rats.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be
10 administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

15 A further aspect of the invention comprises the use of a compound of formula (I) as defined above in the preparation of a medicament for the treatment of inflammatory disease.

The invention is further illustrated, but not limited by the following Examples in which the following general procedures were used unless stated otherwise.

20 Preparation 1

Ethyl N-(3,4-dichlorobenzyl)-4-nitroindole-2-carboxylate

Ethyl 4-nitroindole-2-carboxylate (26 g) [prepared according to S. M. Parmerter *et. al.* *J. Amer. Chem. Soc.*, 1958, 80, 4621], 3,4-dichlorobenzyl chloride (16 ml), potassium carbonate (17 g) and potassium iodide (2 g) in DMF (250 ml) were stirred at 60°C for 2 hours.

25 The reaction was concentrated *in vacuo* and the residue partitioned between water and dichloromethane. Iso-hexane was added to the combined organic extracts resulting in crystallisation of the product as yellow needles (39 g, 89%) NMR δ (CD₃SOCD₃) 1.30 (t, 3H), 4.32 (q, 2H), 5.93 (s, 2H), 6.88 (dd, 1H), 7.18 (d, 1H), 7.52 (d, 1H), 7.56 (dd, 1H), 7.78 (s, 1H), 8.17 (m, 2H); *M/z* (+)395 (MH⁺), 393.

30

Preparation 2

Ethyl N-benzyl-4-aminoindole-2-carboxylate

A mixture of ethyl 4-nitroindole-2-carboxylate (8.2 g), anhydrous potassium carbonate (6.0 g) and benzyl bromide (4.3 ml) in DMF (100 ml) was stirred at 50-60°C for 2 hours. The solvent was evaporated *in vacuo* and the residue partitioned between dichloromethane and water (250 ml each); the organic layer was separated, dried (MgSO₄) and evaporated to give a yellow solid (12 g), which was dissolved in a mixture of tetrahydrofuran / ethanol (200 ml, 1:1) and stirred while adding a solution of sodium dithionite (26 g) in water (50 ml). The mixture was stirred for 1 hour at 25°C and partitioned between dichloromethane and water (200 ml each), the organic layer was washed with water (100 ml) and dried (MgSO₄). Combined organic extracts were concentrated *in vacuo* and the residue purified by column chromatography using dichloromethane as eluent to give the product as a brown solid (1.4 g, 14%); NMR δ (CD₃SOCD₃) 1.28 (t, 3H), 4.27 (q, 2H), 5.57 (s, 2H), 5.73 (s, 2H), 6.22 (d, 1H), 6.62 (d, 1H), 6.95 - 7.05 (m, 3H), 7.15 - 7.30 (m, 3H), 7.60 (s, 1H).

Preparation 3

Ethyl N-(3,4-dichlorobenzyl)-4-nitroindole-2-carboxylate

Sodium hydroxide (3M, 20 ml) was added to a vigorously stirred solution of ethyl 4-nitroindole-2-carboxylate (4 g), 3,4-dichlorobenzyl chloride (4.73 ml) and tetra-*n*-butylammonium hydrogensulphate (0.2 g) in dichloromethane (60 ml). The reaction was stirred for 48 hours then partitioned between 2M HCl and dichloromethane. Combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* and the residue purified by column chromatography using *iso*-hexane : 20% ethyl acetate as eluent to give the product as a yellow crystalline solid (5.26 g, 78%); NMR δ (CD₃SOCD₃) 1.3 (t, 3H), 4.3 (q, 2H), 5.95 (s, 2H), 6.9 (m, 1H), 7.6 (m, 4H), 8.2 (t, 2H); *M/z* (+) 393.3 (*M*⁺).

Ethyl N-(3,4-dichlorobenzyl)-4-aminoindole-2-carboxylate

A solution of ethyl N-(3,4-dichlorobenzyl)-4-nitroindole-2-carboxylate (2.41 g) in tetrahydrofuran (100 ml) was stirred in the presence of titanium trichloride (15% aqueous solution, 50 ml) at room temperature overnight. The reaction was treated with 40% sodium hydroxide solution and extracted with 5% methanol in dichloromethane. Combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to give the product as a brown solid

(1.98 g, 89%); NMR d (CD₃SOCD₃) 1.3 (t, 3H), 4.2 (q, 2H), 5.7 (s, 4H), 6.2 (d, 1H), 6.6 (d, 1H), 7.0 (m, 2H), 7.25 (m, 1H), 7.5 (d, 1H), 7.6 (m, 1H); *M/z* (+) 363.3 (*MH*⁺).

5 Preparation 4

Ethyl 4-chloroacetamido-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate

Ethyl 4-amino-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (2.03 g), chloroacetyl chloride (0.5 ml) and triethylamine (4.0 ml) were stirred in dichloromethane (50 ml) for 16 hours. The reaction was washed with water, dried (MgSO₄) and concentrated *in vacuo*. The residue was triturated with toluene to give the product as a pale grey solid (1.61 g, 65%); NMR d (CD₃SOCD₃) 1.28 (t, 3H), 4.30 (q, 2H), 4.40 (s, 2H), 5.81 (s, 2H), 6.88 (dd, 1H), 7.30 (m, 3H), 7.50 (d, 1H), 7.76 (s, 1H), 7.78 (d, 1H), 10.19 (brs, 1H); *M/z* (-) 439 (*M*⁺), 437.

Example 1

15 Compound 2

Ethyl 4-chloroacetamido-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (0.15 g) and morpholine (2.0 ml) were dissolved in methoxyethanol (5.0 ml) and the reaction stirred for 72 hours. The reaction was then poured into water (100 ml) and the resulting solid filtered and dried *in vacuo*. The solid was dissolved in THF (2.5 ml) and methanol (2.5 ml), and to this was added NaOH (3M, 2.0 ml). The reaction was stirred for 16 hours, then concentrated. The residue was dissolved in water, and precipitated by dropwise addition of acetic acid. The resulting solid was filtered and dried *in vacuo* to give the title compound as a white solid (0.1 g, 63%, 2 steps); NMR d (CD₃SOCD₃) 2.58 (t, 4H), 3.29 (s, 2H), 3.65 (t, 4H), 5.82 (s, 2H), 6.90 (dd, 1H), 7.30 (m, 3H), 7.52 (m, 2H), 7.72 (d, 1H), 9.80 (s, 1H); *M/z* (-) 462 (*M*⁺), 460, 25 418.

Example 2

The procedure described in Example 1 above was repeated using the appropriate amines. Thus were obtained the compounds described below.

Compound 3

49% yield, 2 steps; NMR d (CD₃SOCD₃) 2.27 (s, 3H), 2.54 (t, 4H), 2.62 (t, 4H), 3.22 (s, 2H),
5 5.84 (s, 2H), 6.95 (dd, 1H), 7.22 (m, 2H), 7.33 (s, 1H), 7.41 (s, 1H), 7.50 (d, 1H), 7.72 (d,
1H), 9.75 (s, 1H); *M/z* (-) 475 (*M*⁻), 473, 429, 109.

Compound 6

14% yield, 2 steps; *M/z* (-) 510 (*M*⁻), 508, 464.

10

Example 3**Di-ester of Compound 8**

Ethyl 4-chloroacetamido-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (0.4 g), glycine
methyl ester hydrochloride (0.57 g) and triethylamine (1.25 ml) were dissolved in
15 methoxyethanol (4.0 ml) and the reaction heated at 100°C for 6 hours. The reaction was
cooled and partitioned between water and ethyl acetate. Combined organic extracts were
dried (MgSO₄) and concentrated and the residue purified by chromatography using toluene :
ethyl acetate (1:1) as eluent to give the product, ethyl 4-[(*N*-(methoxycarbonylmethyl)-
glycyl)amino]-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate, as a pale yellow solid (0.17 g,
20 38%); NMR d (CD₃SOCD₃) 1.28 (t, 3H), 3.44 (s, 2H), 3.50 (s, 2H), 3.63 (s, 3H), 4.28 (q, 2H),
5.82 (s, 2H), 6.88 (dd, 1H), 7.10 - 7.30 (m, 4H), 7.50 (d, 1H), 7.69 (s, 1H), 7.80 (dd, 1H),
10.00 (brs, 1H); *M/z* (+) 494, 492 (*M*⁺).

Example 4**25 Di-ester of Compound 11**

Methanesulphonyl chloride (0.1 ml) was added to stirred solution of ethyl 4-[(*N*-
(methoxycarbonylmethyl)glycyl)amino]-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (0.33 g)
and triethylamine (0.47 ml) in dichloromethane (4.0 ml) and the reaction stirred for 3 hours.
The reaction was poured into water and extracted with ethyl acetate. Combined organic
30 extracts were dried (MgSO₄) and concentrated and the residue triturated with ether, filtered
and dried *in vacuo* to give the product as a white solid (0.24 g, 63%); NMR d (CD₃SOCD₃)

1.27 (t, 3H), 3.10 (s, 3H), 3.67 (s, 3H), 4.20 (s, 2H), 4.28 (q+s, 2H+2H), 5.82 (s, 2H), 6.87 (dd, 1H), 7.28 (m, 3H), 7.50 (d, 1H), 7.80 (m, 2H), 10.00 (brs, 1H); M/z (+) 572, 570 (M^+).

5 Example 5

The procedure described in the Example 4 above was repeated using the appropriate acid chloride. Thus was obtained the compound described below.

Di-ester of Compound 12

10 64% yield; M/z (-) 534 (M^+), 532.

Example 6

Di-ester of Compound 14

Sarcosine ethyl ester hydrochloride (1.23 g) and potassium carbonate (1.11 g) were
15 added to a solution of ethyl 4-chloroacetamido-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (700 mg) in acetone (25 ml), stirred and heated at 65°C overnight. The reaction was partitioned between water (50 ml) and ethyl acetate (50 ml), extracted with ethyl acetate (2 x 50 ml), and dried ($MgSO_4$). The combined organic extracts were concentrated *in vacuo*, and the residue purified by column chromatography using 30% ethyl acetate : toluene as eluent, to
20 afford the product as a yellow solid (768 mg, 92%); NMR d (CD_3SOCD_3) 1.21 (t, 3H), 1.28 (t, 3H), 2.45 (s, 3H), 3.42 (s, 2H), 3.53 (s, 2H), 4.16 (q, 2H), 4.30 (q, 2H), 5.81 (s, 2H), 6.88 (d, 1H), 7.27 (m, 2H), 7.52 (d, 1H), 7.67 (s, 1H), 7.84 (d, 1H), 9.95 (s, 1H), M/z (+) 520.3 (MH^+)

Example 7

25 The procedure described in Example 6 above was repeated using the appropriate amine. Thus was obtained the compound described below.

Diester of Compound 13

93% yield; NMR d (CD_3SOCD_3) 1.15 (t, 3H), 1.28 (t, 3H), 3.52 (s, 3H), 3.57 (s, 3H), 3.87 (s, 2H), 4.10 (q, 2H), 4.31 (q, 2H), 5.83 (s, 2H), 6.90 (d, 1H), 7.15 - 7.44 (m, 8H), 7.53 (d, 1H),
30 7.67 (s, 1H), 7.83 (d, 1H); M/z (+) 596.5 (MH^+).

Example 8**5 Di-ester of Compound 15**

A solution of methyl iodide (0.026 ml) in DMF (2 ml) was added to a solution of sodium hydride (15 mg, 60% in mineral oil) and ethyl 4-[(*N*-benzyl-*N*-ethoxycarbonylmethyl)glycyl]amino-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (the diester of Compound 13) (200 mg) in DMF (4 ml), and stirred under an atmosphere of argon at ambient temperature for 4 hours. The reaction was quenched with water (50 ml) and extracted with ethyl acetate (3 x 50 ml), and the combined organic extracts were dried (MgSO₄), and concentrated *in vacuo* to afford the product as a pale brown oil (93 mg, 45%); NMR d (CD₃SOCD₃) 1.05 (t, 3H), 1.30 (t, 3H), 3.21 (s, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.70 (s, 2H), 3.93 (q, 2H), 4.30 (q, 2H), 5.84 (s, 2H), 6.90 (d, 1H), 7.01 (d, 1H), 7.07 - 7.40 (m, 8H), 7.48 - 7.64 (m, 2H); *M/z* (+) 610.5 (MH⁺).

Example 9**Compound 8**

Ethyl 4-[(*N*-(methoxycarbonylmethyl)glycyl)amino]-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (0.15 g) was dissolved in THF / methanol (1:1) (10 ml) and sodium hydroxide (2M, 2.5 ml) was added and the reaction stirred for 16 hours. The reaction was then concentrated *in vacuo* and the residue dissolved in water. The solution was acidified by dropwise addition of acetic acid, resulting in the precipitation of a white solid which was filtered, washed with water and dried *in vacuo* to give the desired end product as a white solid (108 mg, 79%); NMR d (CD₃SOCD₃) 3.40 (s, 2H), 3.64 (s, 2H), 5.82 (s, 2H), 6.92 (dd, 1H), 7.20 - 7.38 (m, 3H), 7.50 (d, 1H), 7.62 (s, 1H), 7.78 (d, 1H), 10.15 (brs, 1H).

Example 10

The procedure described in Example 9 above was repeated using the appropriate ester. Thus were obtained the compounds described below.

Compound 11

79% yield; NMR d (CD₃SOCD₃) 3.10 (s, 3H), 4.02 (s, 2H), 4.20 (s, 2H), 5.83 (s, 2H), 6.88 (dd, 1H), 7.25 (m, 3H), 7.50 (d, 1H), 7.75 (s, 1H), 7.80 (d, 1H), 10.49 (brs, 1H); *M/z* (-) 528 (*M*⁺), 526, 360, 358, 289, 253, 217.

Compound 12

78% yield; NMR d (CD₃SOCD₃) 2.00 (d, 3H), 4.03 (s, 1H), 4.20 (s, 1H), 4.23 (s, 1H), 4.40 (s, 1H), 5.82 (s, 2H), 6.88 (m, 1H), 7.25 (m, 3H), 7.52 (dd, 1H), 7.76 (m, 2H), 10.13 (brs, 1H); *M/z* (-) 492 (*M*⁺), 490, 324, 253, 224.

Compound 14

60% yield; NMR d (CD₃SOCD₃) 2.46 (s, 3H), 3.38 (s, 2H), 3.42 (s, 2H), 5.88 (s, 2H), 6.92 (d, 1H), 7.20 (m, 2H), 7.31 (s, 1H), 7.50 (m, 2H), 7.82 (d, 1H); *M/z* (-) 462.2 (*M-H*⁺).

Compound 15

15% yield; NMR d (CD₃SOCD₃) 3.21 (s, 2H), 3.31 (s, 3H), 3.40 (s, 2H), 3.69 (s, 2H), 5.83 (s, 2H), 6.90 (d, 2H), 6.98 (d, 2H), 7.15 (m, 6H), 7.27 (t, 1H), 7.39 (s, 1H), 7.53 (m, 2H); *M/z* (-) 554.3 (*M-H*⁺).

Compound 13

25% yield; NMR d (CD₃SOCD₃) 3.44 (s, 2H), 3.46 (s, 2H), 3.85 (s, 2H), 5.91 (s, 2H), 6.87 (m, 1H), 7.13 - 7.36 (m, 6H), 7.40 (m, 2H), 7.53 (m, 2H), 7.78 (d, 1H), *M/z* (-) 538.2 (*M-H*⁺), 253.2.

Example 11***N*-Benzyl-4-(2-(pyrid-2-yl)thiophene-5-sulphonyl)aminoindole-2-carboxylic acid
(Compound 1)**

To a solution of ethyl *N*-benzyl-4-aminoindole-2-carboxylate (140 mg) and pyridine (0.08 ml) in dichloromethane (10 ml) at 20°C was added 2-(pyrid-2-yl)thiophene-5-sulphonyl chloride (140 mg) and the reaction stirred for 2 hours. The mixture was washed with HCl (2M, 10 ml), the organic layer was concentrated *in vacuo* and the residue purified by

chromatography on silica using ethyl acetate as eluent, to give a yellow solid which was dissolved in ethanol (50 ml) at 60°C and treated with NaOH (2M, 4.0 ml) with stirring for 2 hours. The solvent was evaporated *in vacuo*, the residue dissolved in water (50 ml) and filtered. The clear yellow filtrate was acidified with 2N HCl and extracted with

5 dichloromethane / methanol (9:1, 100 ml). The organic layer was dried (MgSO₄) and evaporated to give a pale brown solid, which was triturated with ether to give the product as an off white powder (150 mg, 63%, 2 steps); NMR d (CD₃SOCD₃) 5.87 (s, 2H), 6.9 - 7.1 (m, 9H), 7.30 (dd, 2H), 7.43 (d, 1H), 7.63 (d, 1H), 7.81 (dd, 1H), 7.96 (d, 1H), 8.50 (d, 1H); *M/z* (-) 488 (*M-H*⁺).

10

Example 12

The procedure described in Example 11 above was repeated using the appropriate aminoindole and sulphonyl chloride. Thus were obtained the compounds described below.

15

4-(4-Acetylaminobenzenesulphonyl)amino-*N*-(3,4-dichlorobenzyl)indole-2-carboxylic acid (Compound 4)

66% yield (2 steps); NMR d (CD₃SOCD₃) 2.00 (s, 3H), 5.75 (s, 2H), 6.80 (dd, 1H), 6.92 (d, 1H), 7.12 (dd, 1H), 7.22 (m, 2H), 7.48 (d, 1H), 7.56 (s, 1H), 7.66 (s, 4H), 10.24 (brs, 1H),
20 10.45 (brs, 1H); *M/z* (-) 532 (*M-H*⁺), 530.

N-(3,4-Dichlorobenzyl)-4-(2-(pyrid-2-yl)thiophene-5-sulphonyl)aminoindole-2-carboxylic acid (Compound 5)

69% yield (2 steps); NMR d (CD₃SOCD₃) 5.80 (s, 2H), 6.80 (dd, 1H), 7.0 - 7.5 (m, 8H), 7.68
25 (d, 1H), 7.83 (dd, 1H), 7.92 (d, 1H), 8.48 (dd, 1H); *M/z* (-) 558 (*M-H*⁺), 556.

N-(3,4-Dichlorobenzyl)-4-(1-methylimidazole-4-sulphonyl)aminoindole-2-carboxylic acid (Compound 7)

66% yield (2 steps); NMR d (CD₃SOCD₃) 3.60 (s, 3H), 5.78 (s, 2H), 6.86 (dd,
30 1H), 7.04 (1H, d), 7.15 (dd, 1H), 7.20 (d, 1H), 7.30 (d, 1H), 7.50 (d, 1H), 7.68 (m, 2H), 7.75 (s, 1H), 10.20 (brs, 1H); *M/z* (-) 479 (*M-H*⁺), 477.

N-(3,4-Dichlorobenzyl)-4-(2-chloropyridyl-5-sulphonyl)aminoindole-2-carboxylic acid
(Compound 9)

30% yield (2 steps); NMR d (CD₃SOCD₃) 5.85 (s, 2H), 6.83 (d, 1H), 6.93 (dd, 1H), 7.03 (dd, 1H), 7.15 (d, 1H), 7.20 (s, 1H), 7.26 (s, 1H), 7.46 (d, 1H), 7.60 (d, 1H), 8.05 (dd, 1H), 8.62 (d, 1H); *M/z* (-) 512 (*M-H*⁺), 510, 508.

Example 13

Methyl N-(3,4-dichlorobenzyl)-4-(dimethylcarbamoyloxy)indole-2-carboxylate (Methyl ester of Compound 10)

Dimethylcarbamyl chloride (83 mg) was added to a stirred solution of methyl *N*-(3,4-dichlorobenzyl)-4-hydroxyindole-2-carboxylate (150 mg), triethylamine (65 mg) and DMAP (5 mg) in dichloromethane. The reaction was stirred for 16 hours at room temperature under an atmosphere of nitrogen. The reaction was washed with hydrochloric acid (2M, 70 ml), saturated aqueous sodium hydrogencarbonate solution, water and saturated sodium chloride solution. Combined organic extracts were dried (MgSO₄), concentrated *in vacuo* and the residue purified by column chromatography using 60% ethyl acetate : *iso*-hexane as eluent to give the product as a colourless gum (132 mg, 74%); NMR d (CD₃SOCD₃) 2.94 (s, 3H), 3.12 (s, 3H), 3.81 (s, 3H), 5.82 (s, 2H), 6.91 (m, 2H), 7.21 (s, 1H), 7.27 - 7.36 (m, 2H), 7.46 (d, 1H), 7.52 (d, 1H); *M/z* (+) 421 (*MH*⁺).

Example 14

N-(3,4-Dichlorobenzyl)-4-(dimethylcarbamoyloxy)indole-2-carboxylic acid (Compound 10)

Desesterification of the compound of Example 13 using the method described in Example 9 above yielded Compound 10. 93% yield; NMR d (CD₃SOCD₃) 2.94 (s, 3H), 3.11 (s, 3H), 5.91 (s, 2H), 6.82 (d, 1H), 6.94 - 7.03 (m, 2H), 7.18 (t, 1H), 7.29 - 7.39 (m, 2H), 7.50 (d, 1H); *M/z* (-) 405 (*M-H*⁺).

Example 15

Biological Assays for hMCP-1 Antagonists

The following biological test methods, data and Examples serve to illustrate the present invention.

Abbreviations:

ATCC	American Type Culture Collection, Rockville, USA.
BCA	Bicinchroninic acid, (used. with copper sulphate, to assay protein)
BSA	Bovine Serum Albumin
DMEM	Dulbecco's modified Eagle's medium
EGTA	Ethylenebis(oxyethylenitrilo)tetraacetic acid
FCS	Foetal calf serum
HEPES	(N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid])
HBSS	Hank's Balanced Salt Solution
hMCP-1	Human Monocyte Chemoattractant Protein-1
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of

5 thermostable DNA polymerase.

Binding Buffer is 50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% foetal calf serum, adjusted to pH 7.2 with 1 M NaOH.

Non-Essential Amino Acids (100X concentrate) is: L-Alanine, 890 mg/l;

L-Asparagine, 1320 mg/l; L-Aspartic acid, 1330 mg/l; L-Glutamic acid, 1470 mg/l; Glycine,
10 750 mg/l; L-Proline, 1150 mg/l and; L-Serine, 1050 mg/l.

Hypoxanthine and Thymidine Supplement (50x concentrate) is: hypoxanthine, 680 mg/l and; thymidine, 194 mg/l.

Penicillin-Streptomycin is: Penicillin G (sodium salt); 5000 units/ml; Streptomycin sulphate, 5000 µg/ml.

15 Human monocytic cell line THP-1 cells are available from ATCC, accession number ATCC TIB-202.

Hank's Balanced Salt Solution (HBSS) was obtained from Gibco; see *Proc. Soc. Exp. Biol. Med.*, 1949, 71, 196.

Synthetic cell culture medium, RPMI 1640 was obtained from Gibco; it contains
20 inorganic salts [Ca(NO₃)₂·4H₂O 100 mg/l; KCl 400 mg/l; MgSO₄·7H₂O 100 mg/l; NaCl 6000

mg/l; NaHCO₃ 2000 mg/l & Na₂HPO₄ (anhyd) 800 mg/l], D-Glucose 2000 mg/l. reduced glutathione 1 mg/l, amino acids and vitamins.

FURA-2/AM is 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)-ethane-*N,N,N',N'*-tetraacetic acid pentaacetoxymethyl ester and was obtained from Molecular Probes, Eugene, Oregon, USA.

Blood Sedimentation Buffer contains 8.5g/l NaCl and 10g/l hydroxyethyl cellulose.

Lysis Buffer is 0.15M NH₄Cl, 10mM KHCO₃, 1mM EDTA

Whole Cell Binding Buffer is 50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% BSA. 0.01% NaN₃, adjusted to pH 7.2 with 1M NaOH.

10 Wash buffer is 50mM HEPES, 1mM CaCl₂, 5mM MgCl₂, 0.5% heat inactivated FCS, 0.5MNaCl adjusted to pH7.2 with 1M NaOH.

General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

15 i) Cloning and expression of hMCP-1 receptor

The MCP-1 receptor B (CCR2B) cDNA was cloned by PCR from THP-1 cell RNA using suitable oligonucleotide primers based on the published MCP-1 receptor sequences (Charo *et al.*, 1994, *Proc. Natl. Acad. Sci. USA*, **91**, 2752). The resulting PCR products were cloned into vector PCR-II™ (InVitrogen, San Diego, CA.). Error free CCR2B cDNA was
20 subcloned as a Hind III-Not I fragment into the eukaryotic expression vector pCDNA3 (InVitrogen) to generate pCDNA3/CC-CKR2A and pCDNA3/CCR2B respectively.

Linearised pCDNA3/CCR2B DNA was transfected into CHO-K1 cells by calcium phosphate precipitation (Wigler *et al.*, 1979, *Cell*, **16**, 777). Transfected cells were selected by the addition of Geneticin Sulphate (G418, Gibco BRL) at 1mg/ml, 24 hours after the cells had
25 been transfected. Preparation of RNA and Northern blotting were carried out as described previously (Needham *et al.*, 1995, *Prot. Express. Purific.*, **6**, 134). CHO-K1 clone 7 (CHO-CCR2B) was identified as the highest MCP-1 receptor B expressor.

ii) Preparation of membrane fragments

CHO-CCR2B cells were grown in DMEM supplemented with 10% foetal calf serum.
30 2 mM glutamine, 1x Non-Essential Amino Acids, 1x Hypoxanthine and Thymidine Supplement and Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). Membrane fragments were prepared using cell lysis/differential centrifugation methods as described

previously (Siciliano *et al.*, 1990, *J. Biol. Chem.*, 265, 19658). Protein concentration was estimated by BCA protein assay (Pierce, Rockford, Illinois) according to the manufacturer's instructions.

iii) Assay

5 ¹²⁵I MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, 133, 529; Amersham International plc]. Equilibrium binding assays were carried out using the method of Ernst *et al.*, 1994, *J. Immunol.*, 152, 3541. Briefly, varying amounts of ¹²⁵I-labeled MCP-1 were added to 7 µg of purified CHO-CCR2B cell membranes in 100 µl of Binding Buffer. After 1 hour incubation at room temperature the binding reaction mixtures
10 were filtered and washed 5 times through a plate washer (Brandel MLR-96T Cell Harvester) using ice cold Binding Buffer. Filter mats (Brandel GF/B) were pre-soaked for 60 minutes in 0.3% polyethylenimine prior to use. Following filtration individual filters were separated into 3.5ml tubes (Sarstedt No. 55.484) and bound ¹²⁵I-labeled MCP-1 was determined (LKB 1277 Gammamaster). Cold competition studies were performed as above using 100 pM ¹²⁵I-labeled
15 MCP-1 in the presence of varying concentrations of unlabelled MCP-1. Non-specific binding was determined by the inclusion of a 200-fold molar excess of unlabelled MCP-1 in the reaction.

Ligand binding studies with membrane fragments prepared from CHO-CCR2B cells showed that the CCR2B receptor was present at a concentration of 0.2 pmoles/mg of
20 membrane protein and bound MCP-1 selectively and with high affinity ($IC_{50} = 110$ pM, $K_d = 120$ pM). Binding to these membranes was completely reversible and reached equilibrium after 45 minutes at room temperature, and there was a linear relationship between MCP-1 binding and CHO-CCR2B cell membrane concentration when using MCP-1 at concentrations between 100 pM and 500 pM.

25 Test compounds dissolved in DMSO (5 µl) were tested in competition with 100 pM labelled MCP-1 over a concentration range (0.01-50 µM) in duplicate using eight point dose-response curves and IC_{50} concentrations were calculated.

Compounds tested of the present invention had IC_{50} values of 50 µM or less in the hMCP-1 receptor binding assay described herein. For example Compound 2 in Table 1
30 showed IC_{50} of 1.17 µM in hMCP-1.

b) MCP-1 mediated calcium flux in THP-1 cells

The human monocytic cell line THP-1 was grown in a synthetic cell culture medium RPMI 1640 supplemented with 10 % foetal calf serum, 6mM glutamine and Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). THP-1 cells were washed in HBSS (lacking Ca^{2+} and Mg^{2+}) + 1 mg/ml BSA and resuspended in the same buffer at a density of 3×10^6 cells/ml. The cells were then loaded with 1mM FURA-2/AM for 30 min at 37°C, washed twice in HBSS, and resuspended at 1×10^6 cells/ml. THP-1 cell suspension (0.9 ml) was added to a 5 ml disposable cuvette containing a magnetic stirrer bar and 2.1 ml of prewarmed (37°C) HBSS containing 1 mg/ml BSA, 1 mM MgCl_2 and 2 mM CaCl_2 . The cuvette was placed in a fluorescence spectrophotometer (Perkin Elmer, Norwalk, CT) and preincubated for 4 min at 37°C with stirring. Fluorescence was recorded over 70 sec and cells were stimulated by addition of hMCP-1 to the cuvette after 10 sec. $[\text{Ca}^{2+}]_i$ was measured by excitation at 340 nm and 380 nm alternately and subsequent measurement of the intensity of the fluorescence emission at 510 nm. The ratio of the intensities of the emitted fluorescent light following excitation at 340 nm and 380 nm, (R), was calculated and displayed to give and estimate of cytoplasmic $[\text{Ca}^{2+}]$ according to the equation:-

$$[\text{Ca}^{2+}]_i = K_d \frac{(R - R_{\min})}{(R_{\max} - R)} \left(\frac{\text{Sf2/Sb2}}{1} \right)$$

where the K_d for FURA-2 Ca^{2+} complex at 37°C was taken to be 224nm. R_{\max} is the maximal fluorescence ratio determined after addition of 10 mM Ionomycin, R_{\min} is the minimal ratio determined by the subsequent addition of a Ca^{2+} free solution containing 5 mM EGTA, and Sf2/Sb2 is the ratio of fluorescence values at 380 nm excitation determined at R_{\min} and R_{\max} , respectively.

Stimulation of THP-1 cells with hMCP-1 induced a rapid, transient rise in $[\text{Ca}^{2+}]_i$ in a specific and dose dependent manner. Dose response curves indicated an approximate EC_{50} of 2 nm. Test compounds dissolved in DMSO (10µl) were assayed for inhibition of calcium release by adding them to the cell suspension 10 sec prior to ligand addition and measuring the reduction in the transient rise in $[\text{Ca}^{2+}]_i$. Test compounds were also checked for lack of agonist activity by addition in place of hMCP-1.

c) hMCP-1 and RANTES mediated chemotaxis.

In vitro chemotaxis assays were performed using the human monocytic cell line THP-1. Cell migration through polycarbonate membranes was measured by enumerating those passing through either directly by Coulter counting or indirectly by use of a

colourimetric viability assay measuring the cleavage of a tetrazolium salt by the mitochondrial respiratory chain (Scudiero D.A. *et al.* 1988, *Cancer Res.*, **48**, 4827-4833).

Chemoattractants were introduced into a 96-well microtitre plate which forms the lower well of a chemotaxis chamber fitted with a PVP-free 5 µm poresize polycarbonate adhesive framed filter membrane (NeuroProbe MB series, Cabin John, MD 20818, USA) according to the manufacturer's instructions. The chemoattractant was diluted as appropriate in synthetic cell culture medium, RPMI 1640 (Gibco) or supplemented with 2 mM glutamine and 0.5% BSA, or alternatively with HBSS with Ca²⁺ and Mg²⁺ without Phenol Red (Gibco) plus 0.1% BSA. Each dilution was degassed under vacuum for 30 min and was placed (400 µl) in the lower wells of the chamber and THP-1 cells (5x10⁵ in 100 µl RPMI 1640 + 0.5%BSA) were incubated in each well of the upper chamber. For the inhibition of chemotaxis the chemoattractant was kept at a constant submaximal concentration determined previously (1nM MCP-1) and added to the lower well together with the test compounds dissolved in DMSO (final DMSO concentration < 0.05% v/v) at varying concentrations. The chamber was incubated for 2 h at 37°C under 5 % CO₂. The medium was removed from the upper wells which were then washed out with 200 µl physiological saline before opening the chamber, wiping dry the membrane surface and centrifuging the 96-well plate at 600 g for 5 min to harvest the cells. Supernatant (150 µl) was aspirated and 10 µl of cell proliferation reagent, WST-1, {4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-phenyl disulfonate} plus an electron coupling reagent (Boehringer Mannheim, Cat.no. 1644 807) was added back to the wells. The plate was incubated at 37°C for 3 h and the absorbance of the soluble formazan product was read on a microtitre plate reader at 450 nm. The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average absorbance values, standard error of the mean, and significance tests were calculated. hMCP-1 induced concentration dependent cell migration with a characteristic biphasic response, maximal 0.5-1.0 nm.

In an alternative form of the above assay, fluorescently tagged cells can be used in order to assist in end point detection. In this case, the THP-1 cells used are fluorescently tagged by incubation in the presence of 5mM Calcein AM (Glycine, N,N'-[[3',6'-bis(acetyloxy)-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',7'-diyl]bis(methylene)]bis[N-[2-[(acetyloxy)methoxy]-2-oxoethyl]]-bis[(acetyloxy)methyl] ester; Molecular Probes) for 45 minutes in the dark. Cells are harvested by centrifugation and resuspended in HBSS

(without Phenol Red) with Ca^{2+} , Mg^{2+} and 0.1% BSA. 50 μl (2×10^5 cells) of the cell suspension are placed on the filter above each well and, as above, the unit is incubated at 37°C for 2-hours under 5% CO_2 . At the end of the incubation, cells are washed off the upper face of the filter with phosphate buffered saline, the filter removed from the plate and the number of cells attracted to either the underside of the filter or the lower well estimated by reading fluorescence at 485nm excitation, 538nm emission wavelengths (fmax, Molecular Devices). The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average fluorescence values, standard error of the mean, percentage inhibition and IC_{50} of compounds under test and significance tests can be calculated. In addition to MCP-1 induced chemotaxis, this alternative form of the assay was also used to measure inhibition of RANTES (2nM) induced chemotaxis.

d) Binding to human peripheral blood mononuclear cells(PBMCs)

i) Preparation of human PBMCs

Fresh human blood (200ml) was obtained from volunteer donors, collected into sodium citrate anticoagulant to give a final concentration of 0.38%. The blood was mixed with Sedimentation Buffer and incubated at 37°C for 20 minutes. The supernatant was collected and centrifuged at 1700rpm for 5 minutes (Sorvall RT6000D). The pellet obtained was resuspended in 20 ml RPMI/BSA (1mg/ml) and 4 x 5mls of cells were carefully layered over 4 x 5mls of Lymphoprepä (Nycomed) in 15ml centrifuge tubes. Tubes were spun at 1700rpm for 30 minutes (Sorvall RT6000D) and the resultant layer of cells was removed and transferred to 50ml Falcon tubes. The cells were washed twice in Lysis Buffer to remove any remaining red blood cells followed by 2 washes in RPMI/BSA. Cells were resuspended in 5mls of Binding Buffer. Cell number was measured on a Coulter counter and additional binding buffer was added to give a final concentration of 1.25×10^7 PBMCs /ml.

ii) Assay

[^{125}I]MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, 133, 529; Amersham International plc]. Equilibrium binding assays were carried out using the method of Ernst *et al.*, 1994, *J. Immunol.*, 152, 3541. Briefly, 50 μl of ^{125}I -labeled MCP-1 (final concentration 100pM) was added to 40 μl (5×10^5 cells) of cell suspension in a 96 well plate. Compounds, diluted in Whole Cell Binding Buffer from a stock solution of 10mM in DMSO were added in a final volume of 5 μl to maintain a constant DMSO concentration in the assay of 5%. Total binding was determined in the absence of compound. Non-specific

binding was defined by the addition of 5 μ l cold MCP-1 to give a final assay concentration of 100nM. Assay wells were made up to a final volume of 100 μ l with Whole Cell Binding Buffer and the plates sealed. Following incubation at 37°C for 60 minutes the binding reaction mixtures were filtered and washed for 10 seconds using ice cold Wash Buffer using a plate
 5 washer (Brandel MLR-96T Cell Harvester). Filter mats (Brandel GF/B) were pre-soaked for 60 minutes in 0.3% polyethylenimine plus 0.2% BSA prior to use. Following filtration individual filters were separated into 3.5ml tubes (Sarstedt No. 55.484) and bound ¹²⁵I-labeled MCP-1 was determined (LKB 1277 Gammamaster).

Test compound potency was determined by assay in duplicate using six point
 10 dose-response curves and IC₅₀ concentrations were determined.

Compound No. 13 in Table I showed 94% inhibition at 20 μ m.

No physiologically unacceptable toxicity was observed at the effective dose for compounds tested of the present invention.

15 **Example 16**

Pharmaceutical Compositions

The following Example illustrates, but is not intended to limit, pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:

20 (a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X.	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0

Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur	488.5
Magnesium	1.5

5

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	to adjust pH to 7.6
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

(f)

<u>Injection II</u>	<u>(10 mg/ml)</u>
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%

(g)

<u>Injection III</u>	(1mg/ml, buffered to pH6)
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%

5 (h)

<u>Aerosol I</u>	<u>mg/ml</u>
Compound X	10.0
Sorbitan trioleate	13.5
Trichlorofluoromethane	910.0
Dichlorodifluoromethane	490.0

(i)

<u>Aerosol II</u>	<u>mg/ml</u>
Compound X	0.2
Sorbitan trioleate	0.27
Trichlorofluoromethane	70.0
Dichlorodifluoromethane	280.0
Dichlorotetrafluoroethane	1094.0

10 (j)

<u>Aerosol III</u>	<u>mg/ml</u>
Compound X	2.5
Sorbitan trioleate	3.38
Trichlorofluoromethane	67.5

Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

(k)

<u>Aerosol IV</u>	<u>mg/ml</u>
Compound X	2.5
Soya lecithin	2.7
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

(l)

<u>Ointment</u>	<u>ml</u>
Compound X	40 mg
Ethanol	300 μ l
Water	300 μ l
1-Dodecylazacycloheptan-2-one	50 μ l
Propylene glycol	to 1 ml

5 Note:


Compound X in the above formulation may comprise a compound illustrated in Examples. The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k)

10 may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.

Claims

1. A compound of formula (I)

5




(I)

X is CH₂ or SO₂

- 10 R¹ is an optionally substituted aryl or heteroaryl ring;

R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁸, -SO₂NHR⁹, tetrazol-5-yl, SO₃H, or a group of formula (VI)



(VI)

- 15 where R⁸ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO₂R¹² where R¹² is alkyl, aryl, heteroaryl, or haloalkyl, or R⁸ is a group-(CHR¹³)_r-COOH where r is an integer of 1-3 and each R¹³ group is independently selected from hydrogen or alkyl; R⁹ is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR¹⁴ where R¹⁴ is alkyl, aryl, heteroaryl or haloalkyl; R¹⁰ and R¹¹ are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl;
- 20

R³ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl,

optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy, optionally substituted cycloalkyl;

R^4 is a group NHCOR^{15} , $\text{NHSO}_2\text{R}^{15}$ or $\text{OCONR}^{16}\text{R}^{17}$ where R^{15} is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl and R^{16} and R^{17} are

- 5 independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R^{16} or R^{17} is other than hydrogen, or R^{16} and R^{17} together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and
- 10 R^5 , R^6 and R^7 are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R^4 is a group NHCOR^{15} , R^{15} is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.

15

2. A compound according to claim 1 wherein a group R^{15} , R^{16} and R^{17} as they appear in the definition of R^4 , is substituted by at least one functional group, or an aryl or heterocyclyl groups, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.

20

3. A compound according to any one of the preceding claims wherein R^4 is a group NHCOR^{15} or $\text{NHSO}_2\text{R}^{15}$ and R^{15} is a substituted alkyl group or an optionally substituted heterocyclyl or optionally substituted phenyl group.

- 25 4. A compound according to claim 3 wherein R^{15} is alkyl substituted by a group of formula $\text{NR}^{19}\text{R}^{20}$ where R^{19} and R^{20} are independently selected from hydrogen or optionally substituted hydrocarbyl, or R^{19} and R^{20} together form an optionally substituted ring which optionally contains further heteroatoms such as $\text{S}(\text{O})_m$, oxygen and nitrogen, n is an integer of 1 or 2, m is 1 or 2.

30


5. A compound according to any one of the preceding claims where R^2 is carboxy.

6. A compound according to any one of the preceding claims wherein R^1 is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

7. A compound according to any one of the preceding claims where X is CH_2 .

8. A process for preparing a compound according to claim 1 which process comprises either

(a) where R^4 is $NHCOR^{15}$ or $NHSO_2R^{15}$, reacting a compound of formula (VII)



(VII)


where X, R^1 , R^3 , R^5 , R^6 and R^7 are as defined in claim 1, and R^2 is a group R^2 as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)

where Z is a leaving group and R^{22} is a group $COR^{15'}$ or $SO_2R^{15'}$ where $R^{15'}$ is group R^{15} as defined in relation to formula (I) or a precursor thereof;

or (b) where R^4 is a group $OCONR^{16}R^{17}$, reacting a compound of formula (VIIA)



(VIIA)

where X, R^{2'}, R¹, R³, R⁵, R⁶ and R⁷ are as defined claim 1 and R² is a group R² as defined in claim 1 or a protected form thereof, with a compound of formula (VIII A)



5

(VIII A)

where Z, R¹⁶ and R¹⁷ are as defined above;

and thereafter if desired or necessary:

- (i) converting a precursor group R^{15'} to a group R¹⁵ and/or converting a group R¹⁵ to a different such group;
 - 10 (ii) deprotecting a group R^{2'} to a group R².
9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 in combination with a pharmaceutically acceptable carrier.
- 15 10. A compound according to any one of claims 1 to 7 for use in the preparation of a medicament for use in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/00260

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D209/42 C07D409/14 C07D403/12 C07D401/12 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 288 743 A (BROOKS ET. AL.) 22 February 1994 (1994-02-22) column 2, line 16 - line 21; claims; examples	1-10
A	WO 93 12780 A (MERRELL DOW PHARMACEUTICALS) 8 July 1993 (1993-07-08) cited in the application claims; examples	1-10
P, Y	WO 99 07351 A (ZENECA) 18 February 1999 (1999-02-18) cited in the application page 18, line 17 - page 19, line 7; claims; examples	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *B* document member of the same patent family

Date of the actual completion of the international search

11 May 2000

Date of mailing of the international search report

18/05/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 00/00260

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 99 07678 A (ZENECA) 18 February 1999 (1999-02-18) cited in the application page 17, line 8 - line 17; claims; examples	1-10
P,X	WO 99 33800 A (HOECHST) 8 July 1999 (1999-07-08) claims	1,7

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/GB 00/00260

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5288743	A	22-02-1994	MX 9307185 A	31-08-1994
			WO 9412179 A	09-06-1994
WO 9312780	A	08-07-1993	US 5318985 A	07-06-1994
			AT 185969 T	15-11-1999
			AU 3150993 A	28-07-1993
			CA 2124799 A	08-07-1993
			DE 69230224 D	02-12-1999
			DE 69230224 T	13-04-2000
			EP 0617616 A	05-10-1994
			JP 7504890 T	01-06-1995
			NZ 246114 A	26-10-1995
			US 5489579 A	06-02-1996
WO 9907351	A	18-02-1999	AU 8638198 A	01-03-1999
			NO 20000573 A	04-02-2000
WO 9907678	A	18-02-1999	AU 8638098 A	01-03-1999
WO 9933800	A	08-07-1999	AU 2052899 A	19-07-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)